NTBL (Notable Labs, Ltd.) Forward P/E Multiple

Official company branding of Notable Labs (NTBL)

The forward P/E ratio of Notable Labs, Ltd. (NTBL) correlates with the implementation of ESG platforms for oncology therapy optimization, while the value of 0.00 expresses the metric level. Business development relies on external IT outsourcing for the creation of AI algorithms and the execution of clinical tests. The stability of operational processes is supplemented by a streamlined express delivery system for biomaterials, which eliminates laboratory delays.

Notable Labs - NTBL Forward P/E Multiple (period 02/21/2024 - 11/02/2024)

Summary analytical data breakdowns for notablelabs.com (NTBL)

- current price and projected stock value:
Stock Quotes Notable Labs Inc.|NTBL - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Notable Labs|NTBL - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value per Share Notable Labs|NTBL - Book Capitalization|Market Value to Book Value Ratio notablelabs.com|NTBL - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital Notable Labs, Ltd.|NTBL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Notable Labs Inc.|NTBL - Company Aggregate Debt|Debt to Book Capitalization Ratio Notable Labs Ltd|NTBL - Long-Term Debt|Company Current Liabilities Notable Labs|Quick Ratio notablelabs.com
- financial results and valuation multiples details:
NTBL - Net Profit|Projected Future Earnings Notable Labs, Ltd.|NTBL - Price to Earnings Ratio|Future Price to Earnings Notable Labs, Ltd.|NTBL - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Notable Labs Ltd|NTBL - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Notable Labs|NTBL - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months notablelabs.com|NTBL - Earnings per share growth in current year|Earnings growth forecast for next year Notable Labs, Ltd.
- sales volume and revenue indicators:
NTBL - Revenue and Sales Volume|Projected Sales Volume Notable Labs Inc.|NTBL - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Notable Labs, Ltd.
Summary company analytics:NTBL notablelabs.com
Brand item of Notable Labs, Ltd.

The forward P/E ratio relates the current market value of Notable Labs, Ltd. (NTBL) to expected net income, measuring the market's willingness to pay a premium for future earnings. For the PPMP IT ecosystem, where commercial success depends on FDA verdicts and clinical trial results, the forward P/E valuation of Notable Labs, Ltd. (NTBL) reflects speculative demand for AI biomaterial analysis patents in the absence of commercialized products.

Competitors of Notable Labs, Ltd. (NTBL)

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT: Forward P/E Multiple|Price to Future Earnings Ratio AONC|BGNE (BeiGene Ltd) - Forward P/E Multiple|CKPT (Checkpoint Therapeutics, Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ELEV|Projected Price to Earnings iCAD Corp ICAD|Future Price to Earnings ikenaoncology.com IKNA|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple